Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note published on Friday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price objective on shares of Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a research note on Monday, March 4th.

Aethlon Medical Stock Performance

Shares of AEMD stock opened at $1.51 on Friday. Aethlon Medical has a 52-week low of $1.40 and a 52-week high of $7.20. The stock has a market cap of $3.96 million, a price-to-earnings ratio of -0.30 and a beta of 1.88. The firm has a fifty day moving average of $1.70 and a 200-day moving average of $1.79.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). On average, sell-side analysts predict that Aethlon Medical will post -4.98 earnings per share for the current year.

Institutional Investors Weigh In On Aethlon Medical

A number of hedge funds have recently made changes to their positions in AEMD. Renaissance Technologies LLC increased its position in shares of Aethlon Medical by 11.6% during the 1st quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after purchasing an additional 28,097 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Aethlon Medical during the 3rd quarter worth about $72,000. Vanguard Group Inc. increased its position in shares of Aethlon Medical by 112.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after purchasing an additional 558,596 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Aethlon Medical during the 3rd quarter worth about $32,000. Finally, HRT Financial LP acquired a new stake in shares of Aethlon Medical during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.